Otros idiomas NOVELSTEM OTC Markets

Acciones

NSTM

US4362331005

Diferido OTC Markets Otros sitios de cotización 16:59:07 05/10/2021			Varia. Cinco días.	Varia. 1 de enero.
0,27 ^USD	+7,57 %		-3,50 %	+44,75 %

01/04	NovelStem International Corp. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
2023	NovelStem International Corp. informa de los resultados del tercer trimestre y de los nueve meses finalizados el 30 de septiembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
NOVELSTEM INTERNATIONAL CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	31/03/23
NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	17/01/23
Novelstem International Corp. Appoints Jan Loeb as President	17/01/23
NOVELSTEM INTERNATIONAL CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	14/11/22
NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers (form 8-K)	04/10/22
NovelStem International Corp. Elects Christine Jenkins as Chief Financial Officer	04/10/22
NovelStem International Corp. Elects Jan Loeb as Principal Executive Officer	04/10/22
NovelStem International Corp. Announces Management Changes	04/10/22
NovelStem Increases NewStem Ownership to 33% as NewStem Prepares for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares	01/12/20
NovelStem International Corp and Newstem Ltd. Announce New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and Covid-19 Resistance	21/04/20
NovelStem International Corp.'s Equity Buyback announced on January 16, 2018, has expired.	15/01/19
Hollywood Media Corp. will Change its Ticker to NSTM from HOLL	26/09/18
Hollywood Media Corp. has Changed its Name to NovelStem International Corp	25/09/18
Hollywood Media Corp. Announces Board Changes	16/07/18
NewStem Ltd. announced that it expects to receive $4 million in funding from Hollywood Media Corp.	16/07/18

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas NOVELSTEM OTC Markets

Acciones

NSTM

US4362331005

Otros idiomas

Filtros